In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes Steps Toward the Market

Executive Summary

Alkermes' $100mm investment in Reliant Pharmaceuticals represents yet one more twist in the drug delivery company's evolution toward a product business. In effect, the deal allows Alkermes to buy into Reliant at a venture valuation and then increase the in-licensing company's value by putting Alkermes products into its marketing program.
Advertisement

Related Content

Reliant: The Expensive Opportunities in Primary Care
Opportunity Cost: How Alkermes Plans to Survive the Long Winter
Feeling No Pain
Terra Infirma: Pharma Dealmaking 2001

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel